Shorla Pharma Announces Partnership with EVERSANA to Support the Launch and Commercialization of T-cell Leukemia Treatment

August 18, 2021

CAMBRIDGE, Mass. , Aug. 17, 2021 /PRNewswire/ — Shorla Pharma (‘Shorla’), a specialty pharmaceutical company and EVERSANA ™, the pioneer of next generation commercial services to the global life sciences industry, today announced a partnership to support the launch and commercialization of Shorla’s oncology portfolio. The new partnership will initially focus on SH-111, an oncology drug designed to treat T-cell leukemia, currently pending U.S. FDA approval.

Read the source article at PR Newswire
2021-08-17 13:14:02

Share This Story!